| Name | Title | Contact Details |
|---|
Arizona Organization of Nurse Executives is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Healthy Directions publishes seven advisor-led newsletters. They are (in order of their first publication with us): Julian Whitaker, M.D.'s Health & Healing Stephen Sinatra, M.D.'s Heart, Health & Nutrition Dr.
CoCentrix is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.